Comparison between 150 mg monthly and 5 mg daily risedronate in postmenopausal osteoporosis; Effects on bone quality and bone remodelling

被引：1
|
作者：
Chavassieux, R. [1 ]
Portero, N. [1 ]
Xu, S.
Eusebio, R.
Delmas, R. [1 ]
Zanchetta, J. [2 ,3 ]
Valter, I. [4 ]
Recker, R. [1 ,5 ]
机构：
[1] INSERM, U831, F-69008 Lyon, France
[2] USAL Univ, IDIM, Buenos Aires, DF, Argentina
[3] USAL Univ, Sch Med, Buenos Aires, DF, Argentina
[4] Ctr Clin & Basic Res, Clin Res, Tallinn, Estonia
[5] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.397
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [1] Oral risedronate 150 mg once monthly is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II results.
    Ste-Marie, L.
    Brown, J. P.
    Beary, J. F.
    Darbie, L.
    Burgio, D. E.
    Racewicz, A.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S111 - S111
  • [2] Once-a-month 150 mg oral risedronate is as effective as oral daily 5 mg risedronate in postmenopausal osteoporosis: Phase II study results
    Ste-Marie, L. G.
    Brown, J. P.
    Beary, J. F.
    Darbie, L.
    Burgio, D. E.
    Racewicz, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S210 - S211
  • [3] Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg
    Epstein, S.
    Jeglitsch, M.
    McCloskey, E.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2951 - 2960
  • [4] Risedronate 5 mg daily for two years prevents bone loss in late postmenopausal women with osteopenia
    不详
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S162 - S162
  • [5] Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
    Ilter, E
    Karalok, H
    Tufekci, EC
    Batur, O
    [J]. CLIMACTERIC, 2006, 9 (02) : 129 - 134
  • [6] Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
    Rackoff, Paula
    [J]. CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 207 - 214
  • [7] Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
    Delmas, Pierre D.
    McClung, Michael R.
    Zanchetta, Jose R.
    Racewicz, Artur
    Roux, Christian
    Benhamou, Claude-Laurent
    Mang, Zulema
    Eusebio, Rachelle A.
    Beary, John F.
    Burgio, David E.
    Matzkin, Ellen
    Boonen, Steven
    [J]. BONE, 2008, 42 (01) : 36 - 42
  • [8] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Mengu Sarioglu
    Cigdem Tuzun
    Zeliha Unlu
    Canan Tikiz
    Fatma Taneli
    B. Sami. Uyanik
    [J]. Rheumatology International, 2006, 26 : 195 - 200
  • [9] Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis
    Eriksen, EF
    Melsen, F
    Sod, E
    Barton, I
    Chines, A
    [J]. BONE, 2002, 31 (05) : 620 - 625
  • [10] Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis
    Sarioglu, M
    Tuzun, C
    Unlu, Z
    Tikiz, C
    Taneli, F
    Uyanik, BS
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (03) : 195 - 200
12345